List of Apretude drug patents
Apretude is owned by Viiv Hlthcare.
Apretude contains Cabotegravir.
Apretude has a total of 3 drug patents out of which 0 drug patents have expired.
Apretude was authorised for market use on 20 December, 2021.
Apretude is available in suspension, extended release;intramuscular dosage forms.
Drug patent challenges can be filed against Apretude from January, 2025.
The generics of Apretude are possible to be released after 15 September, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: January, 2025
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic